Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Active, not recruiting · NCT03314636 · Registry updated 2025-08-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. | Neoplasms by Histologic Type, neoplasm, plasma cell neoplasm | Active, not recruiting | Phase 2 | 2025-08-08 | NCT03314636 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nordic Myeloma Study Group | 3 |
| Oslo University Hospital | 327 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Copenhagen | Denmark | 9 |
| Odense University Hospital | Odense | Denmark | 57 |
| Oslo University Hospital | Oslo | Norway | 111 |
| Skåne University Hospital | Lund | Sweden | 39 |